HOMCY CHARLES J (CIK 1192591) reported 12 SEC Form 4 insider transactions across 2 companies over the past 18 months (most recent 2026-06-24). Recent activity: Buy BBIO (3,990 shares), Sell BBIO (788 shares), Buy MAZE (1,489 shares), Sell MAZE (28,423 shares), Sell BBIO (191,662 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-24 | BridgeBio Pharma, Inc. (BBIO) | Director | Buy | 3,990 | $0 |
| 2026-06-23 | BridgeBio Pharma, Inc. (BBIO) | Director | Sell | 788 | $52,221 |
| 2025-11-21 | Maze Therapeutics, Inc. (MAZE) | Director | Buy | 1,489 | $0 |
| 2025-10-27 | Maze Therapeutics, Inc. (MAZE) | Director | Sell | 28,423 | $0 |
| 2025-08-12 | BridgeBio Pharma, Inc. (BBIO) | Director | Sell | 191,662 | $8.8M |
| 2025-08-12 | BridgeBio Pharma, Inc. (BBIO) | Director | Sell | 58,338 | $2.7M |
| 2025-08-12 | BridgeBio Pharma, Inc. (BBIO) | Director | Sell | 50,000 | $2.4M |
| 2025-06-30 | BridgeBio Pharma, Inc. (BBIO) | Director | Sell | 20,000 | $0 |
| 2025-06-24 | BridgeBio Pharma, Inc. (BBIO) | Director | Buy | 6,589 | $0 |
| 2025-02-04 | Maze Therapeutics, Inc. (MAZE) | Director | Buy | 8,807 | $0 |
| 2025-02-04 | Maze Therapeutics, Inc. (MAZE) | Director | Buy | 20,717 | $0 |
| 2025-02-04 | Maze Therapeutics, Inc. (MAZE) | Director | Buy | 7,422 | $0 |
Source: SEC Form 4 filings · as of 2026-06-24